Tango Therapeutics Hits New 52-Week High of $32.48, Soars 331.98%

Tango Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 32.48 on June 8, 2026. This achievement marks a remarkable 331.98% increase in the company's stock price over the past year, significantly outperforming the S&P 500, which has seen a gain of 23.42% during the same period. With a market capitalization of USD 2,748 million, Tango Therapeutics continues to make strides in its industry, despite being classified as loss-making with a negative return on equity of -29.35%. The company's price-to-book ratio stands at 7.94, indicating a premium valuation relative to its book value. Additionally, the firm carries a debt-to-equity ratio of -0.98, reflecting a unique financial structure. As Tango Therapeutics celebrates this new high, it underscores the company's dynamic performance in a competitive market, highlighting its potential within the biotechnology landscape.